Table 5.
National costs of cancer care in 2010 US billion dollars for 2010 and 2020 using different assumptions of future cancer incidence and survival and increases in the cost of care*
| Site | Cost in US 2010 billion dollars |
|||||||
| 2010 | 2020 |
|||||||
| Base | Base | Trend incidence | Trend survival | Trend incidence and survival | Under trend incidence and survival: cost increase |
|||
| 2% overall | 2% in initial and last year phase | 5% in initial and last year phase | ||||||
| Breast | 16.50 | 20.50 | 18.91 | 20.69 | 19.08 | 23.24 | 21.37 | 25.64 |
| Colorectal | 14.14 | 17.41 | 14.35 | 17.83 | 14.70 | 17.67 | 16.68 | 20.39 |
| Lymphoma | 12.14 | 15.26 | 15.00 | 15.71 | 15.44 | 18.66 | 17.27 | 20.69 |
| Lung | 12.12 | 14.73 | 12.14 | 15.23 | 12.53 | 15.19 | 14.73 | 18.84 |
| Prostate | 11.85 | 16.34 | 15.32 | 16.43 | 15.41 | 18.53 | 16.67 | 19.02 |
| Leukemia | 5.44 | 6.95 | 6.66 | 7.24 | 6.94 | 8.38 | 7.78 | 9.35 |
| Ovary | 5.12 | 6.03 | 4.49 | 6.27 | 4.64 | 5.64 | 5.26 | 6.42 |
| Brain | 4.47 | 5.53 | 5.38 | 5.79 | 5.62 | 6.82 | 6.51 | 8.18 |
| Bladder | 3.98 | 4.91 | 4.41 | 4.98 | 4.47 | 5.38 | 4.90 | 5.71 |
| Kidney | 3.80 | 5.12 | 6.07 | 5.30 | 6.29 | 7.56 | 6.99 | 8.30 |
| Head/Neck | 3.64 | 4.34 | 3.79 | 4.40 | 3.84 | 4.65 | 4.40 | 5.46 |
| Uterus | 2.62 | 3.05 | 2.84 | 3.04 | 2.83 | 3.42 | 3.24 | 4.00 |
| Melanoma | 2.36 | 3.16 | 3.76 | 3.18 | 3.78 | 4.60 | 4.06 | 4.58 |
| Pancreas | 2.27 | 2.83 | 2.81 | 3.16 | 3.13 | 3.80 | 3.75 | 4.92 |
| Stomach | 1.82 | 2.26 | 1.81 | 2.40 | 1.92 | 2.31 | 2.25 | 2.88 |
| Cervix | 1.55 | 1.54 | 1.20 | 1.55 | 1.21 | 1.46 | 1.39 | 1.73 |
| Esophagus | 1.33 | 1.76 | 1.70 | 2.04 | 1.97 | 2.38 | 2.32 | 2.97 |
| All sites | 124.57 | 157.77 | 147.57 | 165.21 | 154.70 | 186.69 | 172.77 | 206.59 |
The 2020 estimates under the base scenario represent prevalence estimates under the assumption of flat incidence and survival trends but dynamic changes in the US population. Incidence trend and survival trend scenarios represent prevalence projections under the assumptions that survival and incidence trends will continue as observed in the last years of data. Incidence trends represent changes due to prevention and risk factor prevalence. Survival trends represent changes in early detection and treatment. Costs scenarios were 2% annual increase in costs in all phases of care (overall) and 2% and 5% annual increase in the initial and last year phases of care.